COMPliance and arthralgia in clinical therapy: The COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 372-377

  Hadji, P ^a   Jackisch, C ^b   Bolten, W ^c   Blettner, M ^d   Hindenburg, H J ^e   Klein, P ^f   Konig K ^g   Kreienberg, R ^h   Rief, W ^a   Wallwiener, D ⁱ   Zaun, S ^j   Harbeck, N ^k  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Klinikum Offenbach   (Germany)

^c Klaus Miehlke Klinik   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e Gynecologic Oncologists eVin Germany (BNGO eV)   (Germany)

^f Dsh Statistical Services GmbH   (Germany)

^g University Women's Hospital ^*

^h UNIVERSITY HOSPITAL ULM   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j ASTRAZENECA   (United Kingdom)

^k UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Anastrozole; Aromatase inhibitors; Arthralgia; Breast neoplasms; Patient compliance

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

AGED; ALOPECIA; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BONE PAIN; BREAST CANCER; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EARLY CANCER; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; INCIDENCE; INSOMNIA; LIMB PAIN; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; XEROSTOMIA; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG SUBSTITUTION; MEDICATION COMPLIANCE; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARTHRALGIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG SUBSTITUTION; FEMALE; HUMANS; INCIDENCE; MEDICATION ADHERENCE; MIDDLE AGED; NITRILES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84893411288     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt513     Document Type: Article

References (30)

1. Aebi S, Davidson T, Gruber G et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6): vi12-vi24.
2. Cuzick J, Sestak I, Cella D et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008; 9: 1143-1148.
3. Lux MP, Wöckel A, Benedict A et al. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer-a healtheconomic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie 2010; 33: 155-166.
4. Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126: 529-537.
5. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl) 2012; 21: 10-19.
6. Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-562.
7. Hadji P, Ziller V, Kyvernitakis J et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013; 138: 185-191.
8. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010; 73: 156-166.
9. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005; 52: 2594-2598.
10. Sestak I, Cuzick J, Sapunar F et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9: 866-872.
11. Bossart M, Becker M, Hadji P et al. Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial. Anticancer Res 2012; 32: 3933-3938.
12. Din OS, Dodwell D, Winter MC et al. Current opinion of aromatase inhibitorinduced arthralgia in breast cancer in the UK. Clin Oncol (R Coll Radiol) 2011; 23: 674-680.
13. Harbeck N, Blettner M, Bolten WW et al. COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, therapy costs and compliance within the first year of adjuvant anastrozole therapy (Abstract P6- 09-08). 2012. http://www.abstracts2view.com/sabcs12/view.php?Nu=SABCS12L_ 408&terms= (13 June 2013, date last accessed).
14. Lintermans A, Laenen A, Van Calster B et al. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol 2013; 24: 350-355.
15. Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-121.
16. Henry NL, Azzouz F, Desta Z et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012; 30: 936-942.
17. Murphy CC, Bartholomew LK, Carpentier MY et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012; 134: 459-478.
18. Hadji P, Kieback DG, Tams J et al. Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol 2012; 23: 2566-2572.
19. Fontein DB, Seynaeve C, Hadji P et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 2013; 31: 2257-2264.
20. Huober JB, Cole BF, Wu J et al. Symptoms of endocrine treatment and outcome: a retrospective analysis of the monotherapy arms of the BIG 1-98 trial. J Clin Oncol 2011; 29(Suppl 15): Abstract 522.
21. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008; 8: 155-161.
22. Hadji P, Blettner M, Harbeck N et al. The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 2013; 24: 1505-1512.
23. Harbeck N, Blettner M, Hadji P et al. Patient's Anastrozole Compliance to Therapy (PACT) program: baseline data and patient characteristics from a populationbased, randomized study evaluating compliance to aromatase inhibitor therapy in postmenopausal women with hormone-sensitive early breast cancer. Breast Care 2013; 8: 110-120.
24. Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J Support Oncol 2007; 5: 139-143.
25. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296: 2563-2571.
26. Levine AM, Richardson JL, Marks G et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5: 1469-1476.
27. Rief W, Bardwell WA, Dimsdale JE et al. Long-term course of pain in breast cancer survivors: a 4-year longitudinal study. Breast Cancer Res Treat 2011; 130: 579-586.
28. Ziller V, Kalder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20: 431-436.
29. Coleman RE, Bolten WW, Lansdown M et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008; 34: 275-282.
30. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64: 465-474.